Harnessing Arginase-2-specific CD8+ T cells to target immunosuppressive Cutaneous T cell Lymphoma.

No abstract is available for this paper.

• Publication year

  2025

• Venue

  British Journal of Dermatology

• Publication date

  2025-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/bjd/ljaf450PMID 41208405
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer

  2025cited by this paper
• Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review

  2024cited by this paper
• Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma

  2022cited by this paper
• Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells

  2022cited by this paper
• Single-cell RNA sequencing unveils the clonal and transcriptional landscape of cutaneous T-cell lymphomas.

  2022cited by this paper
• Genomic and single-cell landscape reveals novel drivers and therapeutic vulnerabilities of transformed cutaneous T-cell lymphoma.

  2022cited by this paper
• Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation

  2021cited by this paper
• Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways.

  2021cited by this paper
• Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome

  2020cited by this paper
• Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

  2019cited by this paper
• Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues.

  2019cited by this paper
• Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

  2018cited by this paper
• Malignant inflammation in cutaneous T‐cell lymphoma—a hostile takeover

  2016cited by this paper
• Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab

  2015cited by this paper
• TH2 Cytokines from Malignant Cells Suppress TH1 Responses and Enforce a Global TH2 Bias in Leukemic Cutaneous T-cell Lymphoma

  2013cited by this paper
• Prognostic value of arginase‐II expression and regulatory T‐cell infiltration in head and neck squamous cell carcinoma

  2013cited by this paper
• Arginase II Expressed in Cancer-Associated Fibroblasts Indicates Tissue Hypoxia and Predicts Poor Outcome in Patients with Pancreatic Cancer

  2013cited by this paper
• Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome

  2012cited by this paper
• Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome

  2008cited by this paper
• FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival

  2007cited by this paper
• Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA.

  1996cited by this paper

• No citing papers are available for this paper.